Study to Evaluate Apple Devices For Identifying Early Parkinson’s Disease

Apple Watch PD App

A recent study presented at the virtual International Congress of Parkinson’s Disease and Movement Disorders 2021, demonstrated that Apple Watches and iPhones can differentiate between individuals with early, untreated Parkinson’s disease (PD) and healthy controls.

The 12-month study included 132 individuals at 17 Parkinson’s Study Group sites, 82 with PD and 50 controls. Ages of the participants were approximately the same in the PD and control groups (63.3 years vs 60.2 years, respectively), but male to female ratios differed between the groups. There were more men in the PD cohort (56% men vs 44% women) and more women in the control cohort (36% vs 64%; P =.03).

Participants with PD were untreated, were no more than 2 years out from diagnosis (mean disease duration, 10.0 ±7.3 months), and were in Hoehn and Yahr stage 1 or 2. Apple Watches and iPhones were provided to participants, all of whom underwent in-clinic assessments at baseline and at months 1, 3, 6, 9, and 12. The assessments included motor and cognitive tasks using the devices, which contained motion sensors.

The phone also contained an app that could assess verbal, cognitive, and other abilities. Participants also wore a set of inertial sensors (APDM Mobility Lab) while performing the MDS-UPDRS Part III motor examination. In addition, there were bi-weekly at-home tasks. Questions and tests on the watch assessed symptoms of mood, fatigue, cognition, and falls as well as cognitive performance involving perceptual, verbal, visual spatial, and fine motor abilities. Both the watch and iPhone were used to gauge gait, balance, and tremor.

The authors concluded that “the WATCH-PD trial is one of the first multi-center, prospective, longitudinal digital markers studies in untreated early PD patients. Preliminary analyses show that devices can differentiate between individuals with early, untreated PD and controls. Further analyses of longitudinal data may provide additional insights including the utility of wearable and mobile devices for measuring functional outcomes in clinical trials.”

Source:

J. Adams, E. Dorsey, T. Ruiz Herrero, WATCH-PD: Wearable Assessments in the Clinic and Home in Parkinson’s Disease: Baseline Analyses [Abstract 364]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/watch-pd-wearable-assessments-in-the-clinic-and-home-in-parkinsons-disease-baseline-analyses/. Accessed September 25, 2021.